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Abstract 
 
Synaptic reorganization in the epileptic hippocampus involves altered excitatory and 
inhibitory transmission besides the rearrangement of dendritic spines, resulting in altered 
excitability, ion homeostasis, and cell swelling. The potassium-chloride cotransporter-2 (KCC2) 
is the main chloride extruder in neurons and hence will play a prominent role in determining the 
polarity of GABAA receptor-mediated chloride currents. In addition, KCC2 also interacts with 
the actin cytoskeleton which is critical for dendritic spine morphogenesis, and for the 
maintenance of glutamatergic synapses and cell volume. 
Using immunocytochemistry, we examined the cellular and subcellular levels of KCC2 
in surgically removed hippocampi of temporal lobe epilepsy (TLE) patients and compared them  
to control human tissue. We also studied the distribution of KCC2 in a pilocarpine mouse model 
of epilepsy. An overall increase in KCC2-expression was found in epilepsy and confirmed by 
Western blots. The cellular and subcellular distributions in control mouse and human samples 
were largely similar; moreover, changes affecting KCC2-expression were also alike in chronic 
epileptic human and mouse hippocampi.  
At the subcellular level, we determined the neuronal elements exhibiting enhanced 
KCC2 expression. In epileptic tissue, staining became more intense in the immunopositive 
elements detected in control tissue, and profiles with subthreshold expression of KCC2 in 
control samples became labelled. Positive interneuron somata and dendrites were more 
numerous in epileptic hippocampi, despite severe interneuron loss.  
Whether the elevation of KCC2-expression is ultimately a pro- or anticonvulsive change, 
or both - behaving differently during ictal and interictal states in a context-dependent manner - 
remains to be established.  
Keywords: GABA, spinogenesis, human TLE, KCC2, hippocampus 
 
Abbreviations: CA = cornu Ammonis; DAB = 3,3‘diamino-benzidine 4 HCl; DG = dentate 
gyrus; EEG= electroencephalogram; GABA = gamma-aminobutyric acid; GluR1 = Glutamate 
receptor 1; KCC2 = Potassium-chloride cotransporter-2; PET = positron emission tomography; 
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pilo = pilocarpine; SE = status epilepticus; str = stratum; SPECT = single-photon emission 
computerized tomography; TLE = temporal lobe epilepsy 
 
 
Introduction 
 
Members of the potassium-chloride cotransporter (KCC) family are known to play 
important roles in cellular ion and water homeostasis (Hoffmann and Dunham, 1995; Lang et 
al., 1998). In addition, they are involved in dendritic spinogenesis (Fiumelli et al., 2013; Li et 
al., 2007) . The potassium-chloride cotransporter-2 (KCC2) acts as a crucial ion-transport 
system in neurons (Payne et al., 1996; Payne, 1997; Rivera et al., 1999). By maintaining low 
intracellular [Cl-], KCC2 is essential for fast hyperpolarizing GABAA receptor-mediated 
inhibition (Kaila et al., 2014a). 
Temporal lobe epilepsy (TLE) is frequently associated with hippocampal pathology 
(Corsellis, 1955; Green, 1991; Margerison and Corsellis, 1966). The main pathological changes 
in the hippocampus are cell loss and synaptic reorganization, but the pattern and degree of 
changes are variable (Blackwood and Corsellis, 1976; Corsellis, 1955; de Lanerolle et al., 2003; 
Green, 1991; Mathern et al., 1997a; McNamara, 1999). The vulnerability of principal cells 
(pyramidal cells of the CA1 region and endfolium) has been studied in hippocampal sclerosis 
and was found to be the most frequent morphological change in the brain of patients with 
chronic temporal lobe epilepsy (Corsellis, 1955; Green, 1991; Magloczky, 2010; Margerison 
and Corsellis, 1966), together with a loss of specific interneuron types (de Lanerolle et al., 1989; 
Magloczky et al., 2000; Robbins et al., 1991; Sloviter, 1987; Toth et al., 2010; Wittner et al., 
2001; Zhang et al., 2009; Zhu et al., 1997).  
Due to the loss of certain interneurons, impairment of GABAergic inhibition was often 
proposed to be the main cause of epileptic seizure generation (Colder et al., 1996; Sloviter, 
1987). However, morphological (Babb et al., 1989; Wittner et al., 2001) and physiological 
(Cossart et al., 2001; Mody et al., 1995; Wilson et al., 1998; Wilson, 1999; Ylinen et al., 1991) 
data have supported the preservation of perisomatic inhibition in epileptic tissue and have 
shown a selective impairment of dendritic inhibition (Cossart et al., 2001). 
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 Several features of excitation become altered in chronic epilepsy, such as the 
sprouting of excitatory fibres (Buckmaster and Dudek, 1997; Laurberg and Zimmer, 1981; 
Sutula et al., 1989), the alteration of postsynaptic AMPA and NMDA receptors (Mathern et al., 
1997b; Mathern et al., 1998), or the rearrangement of dendritic spines (Isokawa, 2000; Swann 
et al., 2000). Since KCC2 is known to have a role in dendritic spinogenesis and the aggregation 
of postsynaptic GluR1-containing AMPA receptors (Fiumelli et al., 2013; Gauvain et al., 
2011), a change in KCC2 level could easily lead to drastic changes in the excitability of the 
neuronal network. 
Moreover, an increasing number of studies have shown that impaired chloride 
homeostasis may lead to a depolarizing effect of GABA (Kaila et al., 1997; Kaila et al., 2014a; 
Kaila et al., 2014b; Smirnov et al., 1999; Viitanen et al., 2010). GABAergic transmission has 
been shown to become excitatory in a minority of principal neurons of the epileptic human 
temporal lobe (Cohen et al., 2002; Huberfeld et al., 2007), as well as in animal models 
(Fujiwara-Tsukamoto et al., 2003; Stein and Nicoll, 2003). This may be due to a decrease in 
KCC2 expression in vulnerable regions or cell types; to bicarbonate-driven Cl- accumulation 
and consequent elevation of interstitial K+ which can lead to an apparently paradoxical, 
excitatory mode of GABAergic transmission (Viitanen et al., 2010); or due to altered potassium 
homeostasis caused by e.g. the ineffective uptake of extracellular potassium by astrocytes 
(Heinemann et al., 2000; Stewart et al., 2010). Thus, the expression of this protein may also be 
involved in the regulation of neuronal volume changes.  It is important to note that KCC2 was 
shown to be expressed mostly in the vicinity of excitatory synapses (Gulyas et al., 2001).  
Although several earlier studies have dealt with the nature of changes affecting KCC2 
(Galanopoulou, 2008; Jaenisch et al., 2010; Okabe et al., 2003; Papp et al., 2008; Puskarjov et 
al., 2012; Rivera et al., 1999)  its subcellular distribution in human hippocampus is unknown, 
and consequently, anatomical alterations of KCC2 expression have never been compared 
between early post-mortem human TLE patients and controls at the electron microscopic level. 
In this study, we took advantage of the unique opportunity to investigate differences in KCC2 
expression in TLE and human control tissue. Importantly, one should take into account that the 
postmortem delay of control human tissue may modify the immunoreactions, therefore we also 
investigated the distribution of KCC2 in an animal model of chronic epilepsy (Karlocai et al., 
2011). Quantitative changes were studied using Western blots. To uncover any changes in the 
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pattern of KCC2 expression in epilepsy, immunohistochemistry was carried out followed by 
light and electron microscopic examination in the chronic phase (both mice and humans). 
 
Experimental procedures 
 
Human samples 
 KCC2-containing elements were examined in the hippocampi of 12 human control 
samples and in 32 temporal lobe samples surgically removed from epileptic patients. Patients 
with intractable temporal lobe epilepsy underwent surgery at the National Institute of Clinical 
Neuroscience, Budapest, within the framework of the "Hungarian Epilepsy Surgery Program". 
Standard anterior temporal lobectomies were performed (Spencer and Spencer, 1985), i.e. the 
anterior third of the temporal lobe was removed together with the temporomedial structures. 
Samples from patient with lesions other than hippocampal sclerosis were not used. Control brain 
samples were obtained from human subjects (37-72 years old), none of whom had a record of 
any neurological disorders. Brains were removed 2-4 hours after death; the autopsy was 
performed in the Department of Forensic Medicine of the Semmelweis University Medical 
School, Budapest. Harvesting of tissues was approved by the local ethics committee, and 
informed consent was obtained from the next of kin. Tissue was obtained and used in 
accordance with the Declaration of Helsinki. All procedures were approved by the Regional and 
Institutional Committee of Science and Research Ethics of Scientific Council of Health 
(TUKEB 5-1/1996). 
In four out of 12 autopsy control hippocampal samples and 18 of the epileptic samples, a 
part of the resected tissue was separated and snap frozen immediately for further Western blot 
analysis. The remaining part of the 18 epileptic samples and further 14 epileptic hippocampal 
samples were dissected into 3-4 mm thick blocks, and immersed into a fixative containing 4% 
paraformaldehyde, 0.05% glutaraldehyde and 0.2% picric acid in 0.1 M phosphate buffer (PB, 
pH=7,4). The fixative was changed every 30 min to a fresh solution during constant agitation for 
6 hours, and then the blocks were postfixed in the same fixative overnight without 
glutaraldehyde. Another 6 control hippocampi (post mortem delay 2-4 hours) were subjected to 
the same procedure. The remaining two control brains (control numbers 10 and 11) were 
removed from the skull 2 hours after death, both internal carotid and vertebral arteries were 
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cannulated, and the brains were perfused first with physiological saline (2 liters in 30 minutes) 
followed by a fixative solution containing 0.05% glutarealdehyde, 4% paraformaldehyde and 
0.2% picric acid in 0.1 M PB (6 liters in 1,5 hour). The hippocampus was removed after 
perfusion and cut into 3-4 mm thick blocks, which were postfixed in the same fixative solution 
without glutarealdehyde overnight.  
 
Animal model of epilepsy 
For the animal model of TLE, 66 CD1 (p25-p37) male mice (Harlan, Italy) were used 
and 47 were treated with pilocarpine. Animals were kept under standard conditions with a 12 h 
dark-light cycle; food and water were supplied ad libitum. Experiments were performed 
according to the guidelines of the Institutional Ethical Codex & the Hungarian Act of Animal 
Care & Experimentation (1998, XXVIII, Section 243 ⁄ 1998). The Animal Care and 
Experimentation Committee of the Institute of Experimental Medicine of Hungarian Academy 
of Sciences and the Animal Health and Food Control Station, Budapest, approved the 
experimental design under the directive 2303/003/FŐV/2006. The experiments are in 
accordance with 86/609/EEC/2 Directives of the European Community, which is in full 
agreement with the regulation of animal experiments in the European Union. Animals were 
randomly assigned to control and experimental groups. Age-matched control mice (n=19) were 
injected with physiological saline or scopolamine, whereas experimental mice were injected 
with intraperitoneal Pilocarpine hydrochloride (340 mg/kg, Sigma-Aldrich, USA) to induce 
status epilepticus (SE). Scopolamine methyl nitrate (5 mg/kg, Sigma-Aldrich, USA) was 
injected 30 minutes in advance to prevent the peripheral cholinergic effects of pilocarpine 
(Karlocai et al., 2011; Magloczky et al., 2010). 
For further details see (Karlocai et al., 2011) and Supplementary experimental 
procedures.  
In the present study animals were sacrificed at different survival times including 30 
minutes (n=2), 2 hours (n=4), 1 to 3 days (n=12), 1 month and 2 months (n=28) after pilocarpine 
administration.  
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Immunocytochemistry 
 Immunocytochemistry for KCC2 was carried out using two polyclonal rabbit KCC2 
antisera. The dilution of the first antibody was 1:500 (used only for human tissue) (Williams et 
al., 1999), whereas it was 1:10 000 for the second antibody (Rivera et al., 1999; Williams et al., 
1999). Since the two antibodies showed virtually the same distribution of KCC2, the latter one 
was used for mouse tissue at a dilution of 1:10 000. For details see Supplementary experimental 
procedures. 
 
Patterns of cell loss 
Using a semiquantitative scale, cell loss was classified as Type 1 (mild cell loss), Type 2 
(patchy cell loss) or Type 3 in the given region. Type 1: 0-10% of the principal cells were lost, 
Type 2: 10-50% was missing (referred to as “non-sclerotic”), Type 3: more than 50% of the 
cells disappeared (referred to as “sclerotic”). In our previous human studies, we found that more 
than 90% of the CA1 principal cells were missing in the sclerotic type, as described earlier 
(Karlocai et al., 2011; Magloczky and Freund, 1993; Toth et al., 2010; Wittner et al., 2001).  
 
Western blot analysis 
Preparation of crude membrane fractions: Tissue for Western blot analyses was collected from 
18 out of 32 epileptic human hippocampi used for immunocytochemistry. The surgically 
removed tissue was cut into blocks in the coronal plane, and one block containing the 
hippocampal head was snap-frozen in liquid nitrogen and stored at – 80°C until processing. The 
adjacent block was processed for immunocytochemistry. Only samples containing all subfields 
of the hippocampus without considerable portions from other regions were selected for the 
study. Snap-frozen control hippocampi were kindly provided by the Lenhossek Human Brain 
Program, Semmelweis University, Budapest (control subjects n=4, males, two of them 37-49 
years old, the other two 60-72 years old). For further details see Supplementary experimental 
procedures. 
Animal samples were obtained from 10 (6 epileptic, sclerotic, and 4 control) mice. Brains were 
removed from the skull, cut in half and the right and left hippocampal hemispheres were 
separated. The right hippocampus was immediately frozen, cut into 2-3 mm thick coronal blocks 
and regions CA1, CA3 and DG were separated with care. The left hemisphere was processed for 
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immersion fixation in an identical way to the human tissue, and immunocytochemistry was 
carried out to verify that cell loss occurred in the animal . For details see Supplementary 
experimental procedures. 
Western blotting: Protein samples for SDS-PAGE were prepared in 1x Laemli sample 
buffer containing 100 mM DTT (final concentration: 2mg/ml), incubated at 65°C for 5-15 min 
and briefly spun. Afterwards quantities of 10 µl were run on a 10% SDS-PAGE in a Bio-Rad 
Mini-Protean Dual Slab Cell. The gels were blotted in Towbin’s buffer (0.025M Tris, pH 8.3, 
0.192M glycine, 20% methanol) for 1 hour at 100V on a 0.2 µm PVDF membrane (Millipore). 
Immediately after blotting, the membranes were transferred to trays filled with Tris-buffered 
saline with 0.05% Tween-20 (TBST) (Sigma-Aldrich) and washed 2x5 min at room 
temperature. Subsequently, the membranes were incubated in 5% non-fat dry milk in TBST at 
room temperature for 1 hour to block non-specific binding sites and thereafter incubated with 
rabbit anti-KCC2 (1:10.000, (Williams et al., 1999)), and monoclonal anti-β-actin (1:5000, 
Sigma) diluted in the same buffer overnight at 4°C. For human samples, the membranes were 
washed 3x10 min with TBST at room temperature and incubated simultaneously with anti-rabbit 
alkaline phosphatase conjugate (Sigma, 1:10.000) and anti-mouse alkaline phosphatase (1:7500, 
Sigma-Aldrich) in 1% BSA-TBST for one hour at room temperature. The membranes were 
washed 3x10min with TBST at room temperature and developed in NBT- BCIP (nitro-blue 
tetrazolium and 5-bromo-4-chloro-3'-indolyphosphate). For mouse samples, biotinylated anti-
rabbit IgG (1:300, Vector) was applied as secondary serum followed by avidin-biotinylated 
horseradish peroxidase complex (ABC, 1:300, Vector). Membranes were then incubated in 3,3'-
Diaminobenzidine tetrahydrochloride (DAB, Sigma) as a chromogene dissolved in TBST and 
the immunoperoxidase reaction was developed by 0.01% H2O2. 
 
Quantitative analysis: The membranes were scanned on a flat-bed scanner, saved and 
analysed using Image J, a public domain NIH Image program (developed at the U.S. National 
Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/). The 
optical densities of KCC2-specific bands were measured and normalized to the β-actin values, 
pooled in three groups for the human tissue (controls, non-sclerotic and sclerotic) and in six 
groups for the mouse tissue (CA1 sclerotic and control, CA3 sclerotic and control, DG sclerotic 
and control). Means and standard deviation values were calculated. After a Shapiro normality 
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test, an independent t- test or Kruskal-Wallis ANOVA followed by a Mann-Whitney U-test 
were used for statistical analysis with the Statistica 9.1 software.  
 
Dependence of KCC2 immunoreactivity on age, fixation and post-mortem delay 
In previous studies we examined several control brains with different post mortem 
delays and ages of both genders for several antigens (Urban et al., 2002; Wittner et al., 2002). 
Briefly, the progression of age proved to influence the quality and quantity of immunostaining, 
i.e., most of the antisera showed weaker staining and lower number of cells in aged subjects. 
Therefore, subjects older than 80 years have been excluded from the detailed analysis in the 
present study. For electron microscopic studies (including the present KCC2 experiments) 
samples were collected with a post-mortem delay of less than 4 hours, since longer post-mortem 
delays resulted in poor ultrastructural preservation. Electron microscopic analysis of these 
samples revealed acceptable ultrastructural preservation even in immersion-fixed controls, 
although it was of poorer quality compared to the perfused tissue (HK10 and HK11). The 
cellular background of immunogold reaction for KCC2 was higher in the control tissue than in 
the immersion-fixed epileptic samples, except for the post-mortem perfused controls (HK10 and 
HK11) and HK6. Therefore, these three controls were used for electron microscopic 
comparison. The preservation of the perfused 2-4 hours post mortem controls (HK10, HK11) 
and immersion fixed HK6 was comparable to our immersion-fixed epileptic samples and to the 
perfused animal tissues. KCC2 staining in individual control subjects (and control animals) 
included in the present study were similar to each other and to previously described 
immunostaining in the rat (Gulyas et al., 2001). 
To examine whether the post-mortem delay per se affects the KCC2 immunoreactivity in 
control samples, eight CD1 mice were anaesthetized with isoflurane, and decapitated after 0, 2 
h, 4 h and 6 h, and two individuals were examined at each post mortem time. The brain was 
removed from the skull, cut into blocks and immersion-fixed in the same way as post mortem 
human samples (see below). After the same immunocytochemistry protocol, the distribution and 
intensity of KCC2 immunostaining was compared to perfusion-fixed mouse hippocampi. We 
found no alteration in KCC2 immunostaining in immersion-fixed mouse hippocampi after 0-4 
hour post mortem delay. In mice with 6 hours post mortem delay, a slight increase in intensity 
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of KCC2 immunoreaction was observed, but the distribution of immunoreactive elements was 
similar at each time point (Fig. S1).  
 
 
RESULTS 
 
 All patients (n = 32) examined in the present study had pharmacoresistant epilepsy of 
temporal lobe origin. The seizure focus was identified by multimodal studies including video-
EEG monitoring, SPECT and/or PET. Patients with different pathological types (type 1-type 2: 
non-sclerotic, type 3: sclerotic samples, see Experimental Procedures for details) were included 
in the study (Table 1). The pattern of hippocampal cell loss was analysed by light microscopy in 
sections immunostained for different neurochemical markers as shown earlier (Magloczky et al., 
2000; Magloczky and Freund, 2005).  
We observed fibre reorganization in all groups of patients at the electron microscopic 
level: mossy fibre reorganization (Magloczky et al., 1997) and sprouting of interneuron axons 
(Magloczky et al., 2010; Toth et al., 2007; Wittner et al., 2001; Wittner et al., 2002; Wittner et 
al., 2005) were present in both sclerotic and non-sclerotic TLE patients.  
The mouse pilocarpine model of TLE displayed a pattern of cell loss and reorganization 
very similar to that seen in human tissue (Cavalheiro et al., 1996; Mello et al., 1993). Therefore, 
we considered them useful for the interpretation of our results concerning alterations of KCC2 
expression in TLE patients, and for examination of the time course of changes in KCC2 
expression during epileptogenesis. In the acute phase (up to 2 hours after pilocarpine injection) 
no cell loss was found, either in the strongly epileptic or in the weakly epileptic group animals. 
In the latent phase (1 day after pilocarpine administration), sensitive cells (certain CA3c 
pyramidal cells, mossy cells, interneurons) were damaged, but mass cell loss was not observed. 
At day three, in the strongly epileptic animal group, large numbers of CA1 pyramidal cells 
showed signs of degeneration. In the chronic phase, a severe cell loss was detected in the CA1-
CA3 and hilar regions affecting pyramidal cells and certain types of interneurons (Karlocai et 
al., 2011; Magloczky et al., 2010), and sclerosis was found in most of the animals in the strong 
group (over 80% of animals). 
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Similar to our previous work we found that seizure activity correlated with the cell loss 
in all three regions (CA1, CA3 and hilus). Correlation proved to be significant by ANOVA in all 
regions (p<0, 01) (Karlocai et al., 2011). 
 
Light microscopic distribution of KCC2 immunostaining in control and epileptic 
hippocampi 
 
The expression pattern of KCC2 was studied in the hippocampi of human patients with 
TLE and in pilocarpine-treated mice. No significant changes were observed between the weakly 
epileptic and control mice regarding KCC2 expression (not shown) and, therefore, the weakly 
epileptic animals were not examined further in this study. 
Human samples 
In control human tissue, KCC2 was found throughout the entire hippocampus, mostly in 
the dendritic layers. In the somatic region the staining was less intense, only some interneurons 
showed a rather strong labelling of cell bodies. Interneurons were identified by their laminar 
distribution and the morphology of their dendrites e.g. smooth dendrites with varicosities, 
bitufted morphology (see (Freund and Buzsaki, 1996). In the CA1 and CA3 regions of controls, 
KCC2 was mainly expressed in a subset dendrites (most likely interneuron dendrites, as they 
were smooth and varicose) (Fig. 1A), and showed a diffuse, faint staining in the entire neuropil 
with a distribution similar to that described previously in rat (Gulyas et al., 2001). In the cornu 
Ammonis, immunopositive principal cell somata were not observed under our conditions, and 
the identity of elements of the diffuse neuropil staining could not be clearly recognized at the 
light microscopic level. The control hilus contained a large number of KCC2-positive smooth 
and spiny dendrites and some faintly stained cell bodies, whereas only a diffuse neuropil 
staining was observed in the stratum moleculare (Fig. 2A, E).  
The general intensity of KCC2 expression was considerably increased in the hippocampi 
of both sclerotic and non-sclerotic TLE patients (Figs. 1 and 2), in parallel with the degree of 
cell loss (Figs. 1 and 2). A larger amount of discrete, KCC2-immunopositive dendrites could be 
seen in the CA1 region in all pathological groups, most noticeably in Type 3 (sclerotic) patients 
(Fig. 1D). Immunopositive dendrites were found throughout the entire width of the remaining 
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part of the CA1 region. In addition, immunopositive interneuron cell bodies - that are rarely 
seen in controls - were present in large numbers in the sclerotic hippocampi (Fig. 1D).  
In the dentate gyrus, KCC2 expression seemed to be increased as well, and the intensity 
of the homogeneous staining was enhanced in the molecular layer, especially in Type 3 patients 
(Fig. 2D). Occasionally, intensely stained complex spines appeared which were never seen in 
controls (Fig. 2E, F).  
We also studied if there was a gender difference in KCC2 upregulation in chronic 
epilepsy. In case of non-sclerotic samples no such difference was found using the Mann-
Whitney U-test (p=0.67). In case of sclerotic samples the test could not be carried out due to the 
very low number of samples deriving from female patients. 
 
Mouse samples 
 In control mouse tissue, distribution of KCC2 was similar to that observed in human 
samples as well as in the rat (described by our group earlier (Gulyas et al., 2001)). The protein 
was abundant throughout the hippocampus with a diffuse neuropil staining in the cornu 
Ammonis and str. moleculare. In addition, immunopositive somata and dendrites could be 
clearly identified in the hilus (Fig. 3A). 
 In epileptic samples with hippocampal sclerosis, the intensity of the staining was 
considerably increased (similarly to what was found in sclerotic human samples), and this 
increase was most pronounced in areas with severe cell loss (Fig. 3D). Increased KCC2 staining 
was mostly found in dendritic regions, e.g. str. moleculare (Fig. 3C), and numerous strongly 
labelled dendrites were observed in CA1, CA3 and hilus (Fig. 3C-E). Moreover, a large number 
of intensely stained KCC2-positive (most probably) mossy and CA3 pyramidal cells were 
present as well (Fig. 3E, F). 
 
Western blot analysis of KCC2 protein level in control and epileptic hippocampi 
Western blot analysis was used to estimate the difference in KCC2 expression levels 
between control and epileptic tissue. To this end, immune reactions were carried out 
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simultaneously with highly specific KCC2 and β-actin antibodies (Fig. 4). β-actin was used as 
an internal control to normalize the KCC2 values. Crude membrane fractions prepared from 
human tissue obtained from four controls and 18 epileptic patients (n=9, Type 1-2 non-sclerotic, 
and n=9, Type 3 sclerotic patients) were run on multiple SDS-PAGE gels, blotted and 
immunostained for KCC2. The normalized KCC2 signal intensity values obtained for control, 
sclerotic and non-sclerotic hippocampi were averaged and presented as bar-graphs in Fig. 4. 
In agreement with our immunohistochemical results, an upregulation of KCC2 was 
detected with Western blot analysis. The most consistent differences were observed between 
non-sclerotic epileptic and control patients. In most non-sclerotic epileptic samples studied, 
KCC2 was significantly upregulated compared to controls, which was reflected in the higher 
intensity of the 140 kDa band in these patients (Fig. 4A). These results were confirmed by an 
independent quantitative analysis using densitometry. The non-sclerotic group was found to be 
significantly different from both the control and the sclerotic group, whereas the sclerotic group 
did not differ significantly from the control group (pixel density was 138±19 for controls, 
212±57 for non-sclerotic and 128 ±19 for sclerotic samples; Kruskal-Wallis ANOVA p=0.006, 
Mann-Whitney U-test control vs. non-sclerotic p=0.029, sclerotic vs. non-sclerotic p=0.004, and 
control vs. sclerotic p=0.52, (Fig. 4A, Fig. S2)). Quite large variation was observed in KCC2 
immunpositivity among surviving cells in epileptic patients with sclerotic hippocampi. The 
number of surviving cells in hippocampal subfields varied among individuals, e.g. the number 
of mossy cells or CA3 pyramidal cells (Lowenstein et al., 1992; Seress et al., 2009). 
To examine this possibility further, the hippocampi of control (n=4) and sclerotic mice 
(n=6) were separated into CA1, CA3 and dentate gyrus (containing the hilus) regions, and 
processed for Western blot analysis. KCC2 and β-actin were visualized with the same antibodies 
used for human blots. In CA1 and dentate gyrus, a significant increase was found in the intensity 
of KCC2 expression (pixel density of CA1 control: 149±28 and sclerotic 237±48, pixel density 
of DG control: 182±20 and sclerotic: 262±22; t-test p<0.01 and p<0.01 for CA1 and dentate 
gyrus, respectively). Increase was found in the CA3 region of sclerotic samples as well, 
although it did not reach the level of significance (pixel density for control: 128±104 and 
sclerotic: 217±147;t-test p=0.09) (parametric tests were used after Shapiro-normality test).  
It is important to note that a large variation was observed among CA3 samples, which 
may be responsible for the lack of statistical significance (Fig. 4B). 
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Subcellular localization of KCC2 immunoreactivity in control and epileptic hippocampi 
 
For more detailed investigations, KCC2-immunostained elements were examined at the 
electron microscopic level in all regions of control and epileptic hippocampi. Visualization of 
KCC2 was carried out either with DAB or pre-embedding immunogold staining. Both DAB and 
immunogold labelling was inhomogeneous; staining appeared in clusters in the membrane and 
never filled it homogeneously. KCC2 appeared in postsynaptic elements, most frequently in 
dendrites and spines, but rarely in somata. Immunolabelled axons or axon terminals were not 
seen and, in agreement with lack of KCC2 mRNA in glia (Rivera et al., 1999), glial elements 
were not stained either, as also reported before (Baldi et al., 2010; Gulyas et al., 2001; Szabadics 
et al., 2006). 
 
Human samples 
 
In control tissue, mostly dendritic elements and some interneuron somata (see 
description of interneuron identification) were stained, whereas principal cells very rarely 
showed KCC2 expression at the level of our detection threshold (Fig. 5C, G).  
In epileptic tissue, the overall expression level of KCC2 was increased and new elements 
became immunoreactive (Fig. 5A, H). However, the majority of the KCC2-immunostained 
elements remained mostly dendrites and spines that displayed an increased amount of 
immunopositive clusters (Fig. 5D). A considerable number of KCC2-immunolabelled spines 
was also present in the epileptic tissue encircled by large mossy terminals in CA3 strata lucidum 
and pyramidale (Fig. 5E upper inset). Although KCC2-stained pyramidal cells were not seen in 
control tissue, KCC2 expression appeared in the somatic membranes of pyramidal cells in all 
pathological types of epileptic human tissue (Fig. 5A, B). Similarly, granule cell bodies also 
expressed KCC2 in all types of TLE patients (Fig. 5H), whereas they were mostly 
immunonegative in control tissue (Fig. 5G). Mossy cell bodies, dendrites and their complex 
spines were KCC2-immunolabelled both in Type 2 (patchy) and in Type 3 (sclerotic) epileptic 
human tissue (Fig. 5E, F).  
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Mouse tissue 
The subcellular localization was very similar in mouse and human samples. In control 
tissue, mostly dendritic shafts (Fig. 6A) and spines receiving asymmetric synapses (Fig. 6G) 
proved to be immunopositive. Principal cells (Fig. 6C) were mostly free of gold particles, 
indicating a much lower KCC2 expression, compared to some interneuron somata which were 
labelled (Fig. 6E).  
In the sclerotic mouse tissue (similarly to what we found in human epileptic tissue) the 
regional distribution of KCC2 was unchanged; however, KCC2 staining appeared to increase in 
surviving elements throughout the hippocampus. In dendritic elements, the number of gold 
particles indicating the presence of KCC2 was increased in the CA1 (Fig. 6B), hilus (Fig. 6H) 
and CA3 (Fig. 6I) compared to controls (Fig. 6A, G). Principal cells did not show KCC2 
staining in control tissue (Fig. 6C), but the expression of the protein was above detection 
threshold in the sclerotic mouse tissue (Fig. 6D). In addition, KCC2-stained membrane 
segments of interneurons became far more abundant in sclerotic tissue compared to controls 
(Fig. 6F).  
 
DISCUSSION 
 
 
The main novel finding in the present study is that the overall expression of KCC2 is 
increased in the hippocampi of TLE patients. This finding is based on the fact that we were 
able to use well preserved human control tissue for quantitative and qualitative comparisons 
of KCC2 expression patterns. Parallel experiments were carried out on chronically epileptic 
mice (and provided essentially identical results) to demonstrate that the upregulation appears 
in chronic animal models as well. In rodent control tissue KCC2 expression has previously 
been observed throughout the somadendritic axis of hippocampal principal cells (Baldi et al., 
2010), nevertheless, in our samples principal cells showed either very low immunoreactivity 
or none. This difference is due to the fact that the antibody in our study was used at a more 
diluted concentration (see Experimental Procedures) in order to limit background staining in 
human samples and to allow detection of a potential upregulation. Indeed, cells containing a 
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very small amount of KCC2 (e.g. pyramidal cell bodies) appeared virtually negative (likely 
false-negative) in control tissue, and became immunopositive only in the epileptic tissue 
when upregulation occurred.  
Western blot analysis of KCC2 protein level provided quantitative evidence for the 
elevation of KCC2 expression in most cases, (except for sclerotic patients where 
considerable cell loss occurs, thus, concealing protein upregulation). The upregulation is 
likely explained, at least in part, by the increased KCC2 immunoreactivity of some neurons 
in epileptic samples. In spite of the well-known loss of certain types of inhibitory cells both 
in human TLE (de Lanerolle et al., 1988; Magloczky et al., 2000) and animal models of 
epilepsy (Houser, 1991; Magloczky and Freund, 1993; Martin and Sloviter, 2001), the 
KCC2-immunopositive interneuron profiles were abundant and contained more numerous 
immunogold particles in the sclerotic CA1, suggesting that not only the surviving principal 
cells, but also the surviving interneurons contribute to the enhancement of KCC2 expression. 
Increase of the KCC2 transcript (mRNA was quantified with PCR) was found 
previously in a chronic model of epilepsy (Reid et al., 2001); however, downregulation of 
KCC2 transcript, protein, and function was observed in slice preparations producing 
epileptiform activity (Puskarjov et al., 2012; Rivera et al., 2002; Wake et al., 2007) 
suggesting that acute synchronous firing activity might activate different mechanisms. 
Nevertheless, the decrease of function may not appear as a global effect; more recent studies 
have shown that the downregulation is limited to specific areas (Kaila et al., 2014b). 
A decrease in KCC2 level occurred in electrically-kindled and pilocarpine-treated 
mice shortly after the induction of status epilepticus (Barmashenko et al., 2011; Pathak et al., 
2007), whereas in the chronic phase KCC2 expression returned to control levels or was even 
upregulated (Pathak et al., 2007), suggesting that a certain level of reorganization upon 
seizure activity is necessary for this increase.  
In human epileptic peritumoral tissue, elevated levels of NKCC1 and KCC2 were 
found (Conti et al., 2011), whereas in different types of cortical focal dysplasia, both 
increased and decreased amounts of KCC2 have been reported (Talos et al., 2012) or an 
alteration in the subcellular distribution of KCC2 has been observed (Aronica et al., 2007).  
The large variability of the findings regarding KCC2 levels in epileptic tissue is likely 
due to differences in epilepsy models (Barmashenko et al., 2011; Rivera et al., 2002), phases 
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(acute, latent, chronic (Pathak et al., 2007) and the regions studied e.g. neocortex (Aronica et 
al., 2007; Bragin et al., 2009; Talos et al., 2012), hippocampus (Munoz et al., 2007), or 
subiculum (Huberfeld et al., 2007; Munoz et al., 2007). Notably, however, the above studies do 
not shed light on differences in KCC2 expression that exist between the healthy and chronically 
epileptic human hippocampus.  
 
The present study highlights the finding that the upregulation of KCC2 can vary 
among hippocampal regions. Thus, in experiments examining changes of KCC2 content in 
the entire hippocampus (Li et al., 2008) some areas with massive cell- as well as KCC2 loss 
may have masked the upregulation occurring in specific  regions. Thus, the degree and 
pattern of cell loss may differ among individuals, resulting in a variability regarding the 
extent of KCC2 upregulation. 
Epileptic seizures are known to cause massive interneuron activity leading to a high 
Cl- load. Consequently, KCC2 would keep functioning in an extrusion mode, contributing to 
a pro-excitatory elevation in extracellular K+ (Kaila et al., 1997; Kaila et al., 2014b; Smirnov 
et al., 1999; Viitanen et al., 2010). Moreover, gold particles indicating the presence of KCC2 
protein are most often found near asymmetric (excitatory) synapses and very rarely near 
symmetric synapses (Gulyas et al., 2001) indicating that a major role of KCC2 upregulation 
might well be linked to changes in excitability at the single synapse level. 
The importance of KCC2 function near excitatory synapses is supported by results 
demonstrating its role in dendritic spinogenesis. Both in vitro (Li et al., 2007) and in vivo 
(Gauvain et al., 2011) studies have shown that KCC2 promotes spine development by 
interacting with the cytoskeleton, and its presence is necessary for the aggregation of 
postsynaptic GluR1 containing AMPA receptors (Fiumelli et al., 2013; Gauvain et al., 2011). 
Previous studies have shown that a generalized spine loss occurs immediately after 
acute status epilepticus. However, this damage was transient and was followed by recovery 
in the chronic phase (Isokawa, 2000). Since changes in KCC2 expression paralleled these 
changes (decrease in the acute phase, recovery and increase in the chronic phase), the 
upregulation of KCC2 seems to play an essential role in the recovery of spine density and the 
aggregation of certain AMPA subunits (Fiumelli et al., 2013; Gauvain et al., 2011). These 
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findings are in line with a recent study showing that an abnormal human variant of the KCC2 
protein disrupts both Cl- extrusion and dendritic spinogenesis (Puskarjov et al., 2014). 
 
Consequences of KCC2 upregulation  
At the network level the increase of KCC2 would appear as proepileptic, since it 
increases excitability by supporting the rearrangement of dendritic spines and the 
aggregation of AMPA receptors. Moreover, it would further increase excitability by 
enhancing GABAergic [K+]o transients leading to the depolarization of neighbouring cells 
(Kaila et al., 1997; Viitanen et al., 2010). However, at the cellular level, the upregulation 
could act in a neuroprotective manner, since the sustained extrusion mode of KCC2 would 
effectively export Cl- which is a prerequisite for efficient inhibition regardless of whether it 
is hyperpolarizing or “shunting” (for discussion, see (Kaila et al., 2014a). At the subcellular 
level, the effect of a KCC2 increase will depend on its localization. In dendritic spines KCC2 
function might be mainly linked to the rearrangement of spines and aggregation of GluR1-
containing AMPA receptors (Fiumelli et al., 2013; Gauvain et al., 2011), thus, altering the 
excitability of the cell. On dendritic shafts the increased KCC2 amount would play a role in 
changes of the cytoskeleton and provide a GABAergic [K+]o transient (Viitanen et al., 2010). 
Similarly, in the perisomatic region, inhibition will increase intracellular [Cl-], triggering the 
extrusion of Cl- and K+ via KCC2. As a result, release of K+ mediated by phasic inhibition 
will contribute to the pacing of the synchronous discharges during epileptic activity. 
Notably, there is an accumulating amount of evidence supporting the idea that interneurons 
are involved also in the triggering of seizures (de Curtis and Gnatkovsky, 2009; Gnatkovsky 
et al., 2008). 
The above discussion reflects the well-known fact that the influence of disease-
related changes in signalling mechanisms at the molecular and cellular level have context-
dependent effects (Kaila et al., 2014b). Moreover, alterations in ionic regulation that alter 
neuronal signalling (“ionic plasticity”) are likely to have several kinds of both disease-
promoting as well as adaptive actions in epileptogenesis and in seizure generation as 
reviewed recently (Kaila et al., 2014b). Thus, it remains to be established whether the 
elevation of KCC2 expression is ultimately a pro- or anticonvulsive change, perhaps exerting 
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qualitatively distinct actions during e.g. ictal and interictal states or during the course of 
disease progression. 
Since cation-chloride cotransporters are potential targets of antiepileptic drug 
development (Kahle et al., 2013; Loscher et al., 2013), it is essential to clarify their changes 
in the brains of human TLE patients. This task is made easier by the recent description of the 
spatiotemporal expression profiles of the entire CCC family in the human brain along with 
important functionally associated molecules (Sedmak et al, 2015, in press). According to the 
present results and earlier data in chronic TLE (Galanopoulou, 2008; Pathak et al., 2007), 
KCC2 expression appears elevated in the epileptic hippocampus. Further studies using, for 
instance, phosphoantibodies (Kahle et al., 2013) are needed to gain more insight into the 
functional relevance of KCC2 upregulation in various neuronal populations.  
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Figure Legends 
 
Figure 1: Light micrographs showing the distribution of KCC2-positive elements in the human 
CA1 stratum oriens of control (A) and different types of epileptic hippocampi (B, C and D). 
Discrete, intense dendritic staining of individual interneurons (arrowheads, A, B, C and D) is 
embedded in a weaker, diffuse neuropil staining. The number of KCC2-immunostained 
dendrites is increased in the epileptic CA1 region, in parallel with the degree of principal cell 
loss (B, C, and D). The highest density of immunostained profiles is seen in the sclerotic CA1 
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(D), where KCC2-immunoreactive interneuron somata are also frequently observed (arrows in 
D). Scales: A-D: 50 µm  
CA1: Cornu Ammonis region 1, KCC2: Potassium-chloride cotransporter-2 
 
Figure 2: Light micrographs showing the distribution of KCC2-positive elements in the dentate 
gyrus of human control (A and E) and epileptic samples with different pathology (B, C, D and 
F). In controls, discrete interneuron dendrites are visible in the stratum moleculare and in the 
hilus (A, arrows). The number of immunopositive dendrites is increased in epileptic samples (B, 
C and D, arrows) and the intensity of faint diffuse staining of the stratum moleculare is 
enhanced. In addition, the density of KCC2-immunostained elements – smooth and spiny 
dendrites (arrows in E) - is profoundly enhanced in the hilus of Type 2 and 3 patients (C, D and 
F). Spines, dendrites and cell bodies of surviving mossy cells (F, large arrows), and dendrites 
with long, complex spines (F, small arrows), show intense KCC2-immunopositivity. Scales: A-
D: 150µm; E, F: 50 µm  
DG: Dentate Gyrus, KCC2: Potassium-chloride cotransporter-2 
 
Figure 3: Light micrographs showing the distribution of KCC2-positive elements in the dentate 
gyrus and CA1 regions of control (A and B) and epileptic (sclerotic) mice (C and D). In control, 
discrete dendrites are visible in the hilus (arrows), whereas diffuse staining of the neuropil 
occurs in stratum moleculare of DG (A) and in strata oriens and radiatum of CA1 (B). In 
epileptic samples, the number of immunopositive dendrites is increased (arrows on C, D and E) 
and the intensity of faint diffuse staining of the stratum moleculare is enhanced (C). In addition, 
the occurrence of KCC2-immunostained somata is increased, both in the hilus (arrows on C and 
F) and in the cornu Ammonis (D and E). Scales: A-D: 50µm  
CA1: cornu Ammonis region 1, DG: Dentate Gyrus, KCC2: Potassium-chloride cotransporter-2 
 
Figure 4. Western blot of crude membrane fractions isolated from epileptic and control 
hippocampi show an upregulation of KCC2. In human tissue, 4 controls were compared to 9 
non-sclerotic and 9 sclerotic samples (patients). Significant differences were found among 
control and non-sclerotic samples; however patients with sclerotic hippocampi showed no 
significant difference compared to control (though 5 out of 9 patients displayed elevated KCC2 
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levels compared to the controls) (A).  In the epileptic sclerotic mouse hippocampus, CA1 CA3 
and DG were separated and compared to controls. A significant increase of KCC2 was found in 
sclerotic CA1 and DG but not in CA3 (B).  
CA1: Cornu Ammonis region 1, CA3: Cornu Ammonis region 3, DG: Dentate Gyrus, KCC2: 
Potassium-chloride cotransporter-2, TLE: Temporal Lobe Epilepsy 
 
Figure 5: Electron micrographs show preembedding immunogold and DAB labelling of KCC2 
in human tissue. Silver-enhanced gold particles signalling KCC2-immunopositivity are present 
on the membrane of CA1 pyramidal cell bodies of TLE patients (A and B, arrows); the same 
cell is shown at the light microscopic level in the upper right small insert in A. The framed area 
is shown at higher power in B. Spines of principal cells receiving asymmetric synaptic input 
were also intensively KCC2-immunoreactive (C, arrows), similarly to interneuron dendrites 
receiving multiple asymmetric synaptic contacts (asterisks) are shown in D. Mossy cell bodies 
(lower insert in E shows the same cell at the light microscopic level) and their dendrites and 
spines (see small upper insert, sp: spine, mt: mossy terminal) are also positive for KCC2 in 
epileptic samples. The framed area is shown at higher power in F, arrows point to the silver-
enhanced gold particles. Granule cell bodies are negative for KCC2 in the control (G), whereas 
their dendrites and somata contain numerous silver-enhanced gold particles in the epileptic cases 
(H, small arrows). Asterisks indicate synapses. Scales: A, E: 5 µm; B, F: 2 µm; G, H: 2.5µm; C, 
D: 0.5µm 
CA1: Cornu Ammonis region1, DG: Dentate Gyrus, KCC2: Potassium-chloride cotransporter-2, 
TLE: Temporal Lobe Epilepsy 
 
Figure 6: Electron micrographs show preembedding immunogold labelling of KCC2 in the 
mouse hippocampus. In control tissue silver-enhanced gold particles indicating KCC2-
immunopositivity are present in the membrane of dendrites (A, arrows), and in dendritic spines 
(G). Principal cell somata appear free of staining (C) whereas the cell body of interneurons may 
express KCC2 (see arrow in E). In epileptic tissue, the density of sliver-enhanced gold particles 
is increased in dendrites and dendritic spines (B, H, I). Principal cell somata become positive for 
KCC2 (D), and a strong upregulation of KCC2-expression can be seen in the membrane of 
certain interneurons (F). Silver-enhanced gold particles are usually present extrasynaptically, 
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near asymmetric synapses (B, H and I). Asterisks indicate synapses. Scales: A, B and G-I: 0,2 
µm; C-F: 0,5µm 
CA1: Cornu Ammonis region1, CA3: Cornu Ammonis region 3, DG: Dentate Gyrus, KCC2: 
Potassium-chloride cotransporter-2 
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Figure 1: Light micrographs showing the distribution of KCC2-positive elements in the human 
CA1 stratum oriens of control (A) and different types of epileptic hippocampi (B, C and D). 
Discrete, intense dendritic staining of individual interneurons (arrowheads, A, B, C and D) is 
embedded in a weaker, diffuse neuropil staining. The number of KCC2-immunostained 
dendrites is increased in the epileptic CA1 region, in parallel with the degree of principal cell 
loss (B, C, and D). The highest density of immunostained profiles is seen in the sclerotic CA1 
(D), where KCC2-immunoreactive interneuron somata are also frequently observed (arrows in 
D). Scales: A-D: 50 µm 
CA1: Cornu Ammonis region 1, KCC2: Type 2 potassium-chloride cotransporter 
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Figure 2: Light micrographs showing the distribution of KCC2-positive elements in the dentate 
gyrus of human control (A and E) and epileptic samples with different pathology (B, C, D and 
F). In controls, discrete interneuron dendrites are visible in the stratum moleculare and in the 
hilus (A, arrows). The number of immunopositive dendrites is increased in epileptic samples (B, 
C and D, arrows) and the intensity of faint diffuse staining of the stratum moleculare is 
enhanced. In addition, the density of KCC2-immunostained elements – smooth and spiny 
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dendrites (arrows in E) - is profoundly enhanced in the hilus of Type 2 and 3 patients (C, D and 
F). Spines, dendrites and cell bodies of surviving mossy cells (F, large arrows), and dendrites 
with long, complex spines (F, small arrows), show intense KCC2-immunopositivity. Scales: A-
D: 150µm; E, F: 50 µm  
DG: Dentate Gyrus, KCC2: Type 2 potassium-chloride cotransporter 
 
Figure 3: Light micrographs showing the distribution of KCC2-positive elements in the dentate 
gyrus and CA1 regions of control (A and B) and epileptic (sclerotic) mice (C and D). In control, 
discrete dendrites are visible in the hilus (arrows), whereas diffuse staining of the neuropil 
occurs in stratum moleculare of DG (A) and in strata oriens and radiatum of CA1 (B). In 
epileptic samples, the number of immunopositive dendrites is increased (arrows on C, D and E) 
and the intensity of faint diffuse staining of the stratum moleculare is enhanced (C). In addition, 
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the occurrence of KCC2-immunostained somata is increased, both in the hilus (arrows on C and 
F) and in the cornu Ammonis (D and E). Scales: A-D: 50µm  
DG: Dentate Gyrus, KCC2: Type 2 potassium-chloride cotransporter 
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Figure 4. Western blot of membrane fractions isolated from epileptic and control hippocampi 
show an upregulation of KCC2. In human tissue, 4 controls were compared to 9 non-sclerotic 
and 9 sclerotic samples, however, due to differences in post-mortem times, only three controls 
were included in statistics (fourth band was excluded). Significant differences were found 
among control and non-sclerotic samples; however patients with sclerotic hippocampi showed 
no significant difference compared to control (though 5 out of 9 patients displayed elevated 
KCC2 levels compared to the controls) (A). In the epileptic sclerotic mouse hippocampus, CA1 
CA3 and DG were separated and compared to controls. A significant increase of KCC2 was 
found in sclerotic CA1 and DG but not in CA3 (B).  
CA1: Cornu Ammonis region1, CA3: Cornu Ammonis region 3, DG: Dentate Gyrus, KCC2: 
Type 2 potassium-chloride cotransporter, TLE: Temporal Lobe Epilepsy 
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Figure 5: Electron micrographs show preembedding immunogold and DAB labelling of KCC2 
in human tissue. Silver-enhanced gold particles signalling KCC2-immunopositivity are present 
on the membrane of CA1 pyramidal cell bodies of TLE patients (A and B, arrows); the same 
cell is shown at the light microscopic level in the upper right small insert in A. The framed area 
is shown at higher power in B. Spines of principal cells receiving asymmetric synaptic input 
were also intensively KCC2-immunoreactive (C, arrows), similarly to interneuron dendrites 
receiving multiple asymmetric synaptic contacts (asterisks) are shown in D. Mossy cell bodies 
(lower insert in E shows the same cell at the light microscopic level) and their dendrites and 
spines (see small upper insert, sp: spine, mt: mossy terminal) are also positive for KCC2 in 
epileptic samples. The framed area is shown at higher power in F, arrows point to the silver-
enhanced gold particles. Granule cell bodies are negative for KCC2 in the control (G), whereas 
their dendrites and somata contain numerous silver-enhanced gold particles in the epileptic cases 
(H, small arrows). Asterisks indicate synapses.  Scales: A,E: 5 µm; B,F: 2 µm; G,H: 2.5µm; C, 
D: 0.5µm 
CA1: Cornu Ammonis region1, DG: Dentate Gyrus, KCC2: Type 2 potassium-chloride 
cotransporter, TLE: Temporal Lobe Epilepsy 
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Figure 6: Electron micrographs show preembedding immunogold labelling of KCC2 in the 
mouse hippocampus. In control tissue silver-enhanced gold particles indicating KCC2-
immunopositivity are present in the membrane of dendrites (A, arrows), and in dendritic spines 
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(G). Principal cell somata appear free of staining (C) whereas the cell body of interneurons may 
express KCC2 (see arrow in E).  In epileptic tissue, the density of sliver-enhanced gold particles 
is increased in dendrites and dendritic spines (B,H,I). Principal cell somata become positive for  
KCC2 (D),  and a strong upregulation of KCC2-expression can be seen in the membrane of 
certain interneurons (F). Silver-enhanced gold particles are usually present extrasynaptically, 
near asymmetric synapses (B,H and I). Asterisks indicate synapses. Scales: A, B and G-I: 
0,2µm; C-F: 0,5µm 
CA1: Cornu Ammonis region1, CA3: Cornu Ammonis region 3, DG: Dentate Gyrus, KCC2: 
Type 2 potassium-chloride cotransporter 
 
 
 
 
 Supplementary Material 
 
Supplementary experimental procedures 
Animal model of epilepsy 
Based on the severity of acute seizures, animals were classified as weakly and strongly 
epileptic using a modified Racine’s scale (Racine, 1972). Mice in the strongly epileptic group 
produced frequent, tonic-clonic seizures with intense motor symptoms (Racine 4-5), while 
members of the weakly epileptic group had rare and mild seizures (Racine 1-3) (Magloczky et 
al., 2010). In addition, chronic recurrent seizures were typical for strongly epileptic mice, and 
hardly ever found in members of the weakly epileptic group (Karlocai et al., 2011).  
The acute phase was studied 30 minutes to 2 hours after the induction of seizures. The period 
examined 1-3 days after the injection was regarded as the latent phase. At day three post-
injection, mass cell loss began in certain animals, therefore, this time point was considered as 
the end of the latent phase. At least 30 days after seizure induction we studied the chronic phase, 
when recurrent seizures could be observed (Karlocai et al., 2011). 
Mice were perfused under equithesine anesthesia (chlornembutal 0.3 mL ⁄ 100 g), first 
with physiological saline (3 min) and then with a fixative containing 0.05% glutaraldehyde, 4% 
paraformaldehyde and 15% picric acid in 0.1 M PB for 30 min.  
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Immunocytochemistry 
 60 µm thick vibratome sections were cut from the blocks, and following washing in PB, 
they were immersed in 30% sucrose for 1-2 days, then freeze-thawed three times over liquid 
nitrogen. Sections were processed for immunostaining as follows: after thorough washing  in 
TRIS buffered saline (TBS, pH, 7.4) several times, endogenous peroxidase activity was blocked 
by 1% H2O2 in TBS for 10 minutes. TBS was used for all the washes (3x10 min between each 
antiserum) and for dilution of the antisera. Non-specific immunostaining was blocked by 5% 
milk powder and 2 % bovine serum albumin for human samples and 10% normal goat serum for 
mouse samples. To ensure that the stained elements are indeed specific for KCC2 two 
polyclonal rabbit KCC2 antisera were used for human tissue. The dilution of the first antibody 
was 1:500 (used only for human tissue) (Williams et al., 1999), whereas it was 1:10 000 for the 
second antibody (Rivera et al., 1999; Williams et al., 1999). Since the two antibodies showed 
exactly the same distribution of KCC2, the latter one was used for mouse tissue at a dilution of 
1:10 000. For analysing cell loss, rabbit anti-GluR2/3 staining was also carried out (Chemicon 
International, 1:100) (not shown). For both KCC2 and GluR2/3 stainings, sections were 
incubated in the antisera for two days at 4oC. For the visualization of the immunopositive 
elements, biotinylated anti-rabbit IgG (1:300, Vector) was applied as secondary serum followed 
by avidin-biotinylated horseradish peroxidase complex (ABC, 1:250, Vector). Sections were 
incubated for 20 minutes in 3,3'-Diaminobenzidine tetrahydrochloride (DAB, Sigma) as a 
chromogene dissolved in TRIS buffer (TB, pH=7.6) and the immunoperoxidase reaction was 
developed by 0.01% H2O2. Sections were then treated with 1% OsO4 in 0.1 M PB for 40 min, 
dehydrated in ethanol (1% uranyl acetate was added at the 70% ethanol stage for 40 min) and 
mounted in Durcupan (ACM, Fluka).  
A preembedding immunogold reaction was carried out in the same way, but after 48 h 
incubation in KCC2 primary antiserum, sections were washed extensively and blocked in 0.8% 
BSA, 0.1% IGGS gelatin (Amersham Life Science) and 5% normal goat serum in TBS for 30 
min. This was followed by incubation with 1 nm gold-labelled goat anti-rabbit IgG (Amersham 
Life Science) diluted 1:50 in 0.8% BSA, 0.1% IGGS gelatin, 0.1 mg/ml glycine and lysine 
(Sigma) and 1% normal goat serum in TBS overnight. After incubation, sections were washed 
and postfixed with 1% glutaraldehyde in TBS for 10 min. The 1 nm gold particles were silver-
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enhanced by IntenSETM M (Amersham Life Science) for 5-15 min. The sections were treated 
with 1% OsO4 in 0.1 M PB for 10 min, and dehydrated in ascending ethanol series and 
embedded in Durcupan (ACM, Fluka). During dehydration, the sections were treated with 1% 
uranyl acetate in 70% ethanol for 30 min.  
 After light microscopic examination, areas of interest were re-embedded and sectioned 
for electron microscopy. Ultrathin serial sections were collected on Formvar-coated single slot 
grids, stained with lead citrate, and examined with a Hitachi 7100 electron microscope. 
For light microscopic investigation of the KCC2-immunoreactive elements, 12 control 
and 32 epileptic human samples were used, whereas 19 control and 47 epileptic mouse 
hippocampi were chosen. For electron microscopic examination three controls and six epileptic 
human samples were taken, whereas five control and eight epileptic mouse hippocampi were 
analysed. All subfields of the control and epileptic hippocampi were examined in the electron 
microscope. 
 
Western blot analysis 
Preparation of crude membrane fractions: Human samples for sodium dodecyl 
sulphate containing polyacrylamide gel electrophoresis (SDS-PAGE) were prepared as follows: 
Tissue was weighed and homogenized in ice-cold lysis buffer: 25mM HEPES, 1mM EDTA, 
6mM MgCl2, 1mM Dithiothreitol (DTT), pH 7.4, supplemented with protease inhibitors 
(Complete, Roche) with a polytron homogenizer for 30 sec at maximum speed. The homogenate 
was adjusted to 10% (w/v) and centrifuged at 700xg for 5 min at 4°C to remove the nuclei. The 
supernatant was collected. The pellets were re-suspended in the original volume of lysis buffer, 
re-homogenized and spun down at 700xg for 5 min at 4°C. The supernatant containing the 
soluble proteins was collected and frozen for later analysis. The membrane pellets were re-
suspended with a pipette using the original volume of lysis buffer and spun down as above. 
Supernatants were discarded, the pellets were resuspended in 1/30 of original volume lysis 
buffer, and the protein content was measured using the Bradford assay (Bradford, 1976).  
Mouse samples for sodium dodecyl sulphate containing polyacrylamide gel 
electrophoresis (SDS-PAGE) were prepared as follows: Tissue was weighed and homogenized 
in ice-cold lysis buffer: 25mM HEPES, 1mM EDTA, 6mM MgCl2, 1mM Dithiothreitol (DTT), 
pH 7.4, supplemented with protease inhibitors (Complete, Roche) with a homogenizer for 10 
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minutes. The homogenate was adjusted to 20% (w/v) and centrifuged at 700xg for 5 min at 4°C 
to remove the nuclei and debris. The supernatant was collected (S1). The pellets were re-
suspended in half of the original volume of lysis buffer, re-homogenized and stored on ice for 
half an hour, then spun down at 700xg for 5 min at 4°C. The supernatant (S2) was collected. 
Supernatant fractions S1 and S2 were mixed and homogenized, then the protein content was 
measured using the Bradford assay (Bradford, 1976). Samples were stored frozen for later 
analysis.  
 
 
 
  
 
39
Supplementary Figure 1: The effect of post-mortem delay on KCC2-staining was examined in 
mice 0, 2, 4 and 6 hours after death (2 individuals each). No alteration was found after 0-4 hour 
post mortem delay (capital letters indicate entire hippocampi, whereas minuscule letters show 
region CA1 in greater magnification). In mice with 6 hours post mortem delay, a slight increase 
in intensity of KCC2 immunoreaction appeared, but the distribution of immunoreactive 
elements was similar at each time point. Scale: A-H: 500 µm, a: 100 µm.    
 
 
 
 
 
 
  
Supplementary Figure 2: Western blots were analysed calculating pixel densities. In non-
sclerotic samples pixel density increased as a function of cell loss (largest in type 2 epileptic 
samples). However, in sclerotic samples pixel density only slightly differed from controls, due 
to intense cell loss. 
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